<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328028</url>
  </required_header>
  <id_info>
    <org_study_id>111050</org_study_id>
    <nct_id>NCT01328028</nct_id>
  </id_info>
  <brief_title>Human Papillomavirus (HPV) Type Distribution in Adult Women Diagnosed With Invasive Cervical Cancer in New Zealand</brief_title>
  <official_title>Hospital-based Epidemiological Study on the Distribution of Human Papillomavirus (HPV) Types in Adult Women Diagnosed With Invasive Cervical Cancer (ICC) in New Zealand</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the distribution of the most frequent types of human
      papillomavirus in women diagnosed with invasive cervical cancer in New Zealand.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of HPV-16 and HPV-18 in women with invasive cervical cancer</measure>
    <time_frame>At least the last 3 years from the time of study start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of other high-risk HPV types in women with invasive cervical cancer</measure>
    <time_frame>At least the last 3 years from the time of study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of HPV-16/ HPV-18 co-infection with other high-risk HPV types in women with invasive cervical cancer</measure>
    <time_frame>At least the last 3 years from the time of study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of low-risk HPV types in women diagnosed with invasive cervical cancer</measure>
    <time_frame>At least the last 3 years from the time of study start</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">244</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Subjects diagnosed with invasive cervical cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Testing of archived cervical cancer tissue samples</intervention_name>
    <description>Cervical samples will be tested for histopathology diagnosis and human papillomavirus deoxyribonucleic acid testing.</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>Log sheet</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cervical specimen
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women aged &gt;= 18 years at the time that the cervical specimen was taken, and diagnosed with
        invasive cervical cancer stage IB or greater
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A female aged 18 years and above at the time of cervical specimen collection, and
             currently residing in New Zealand.

          -  Histological diagnoses of invasive cervical cancer stage IB or greater, within at
             least the last 3 years.

          -  Written informed consent obtained from the subject/ next of kin/ Legally acceptable
             representative.

          -  Availability of cervical specimen on which the diagnosis was made prior to any
             chemotherapy or radiotherapy.

          -  The cervical specimen should be of appropriate size and with regular tissue specimens.

          -  The cervical specimen should be adequately preserved.

          -  All links to the subject's identity should be removed from the paraffin block.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>New Zealand</country>
  </removed_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2011</study_first_submitted>
  <study_first_submitted_qc>March 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2011</study_first_posted>
  <last_update_submitted>August 23, 2012</last_update_submitted>
  <last_update_submitted_qc>August 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Invasive cervical cancer</keyword>
  <keyword>Human papillomavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

